Company intelligence / Profile preview

Fable Biyoteknoloji

Cambridge, Massachusetts, United Statesglobaldata.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Fable Therapeutics is developing next-generation biologic drugs for metabolic diseases using a proprietary AI-driven protein design platform. The company has not yet reached clinical trials but aims to address validated targets in obesity and related comorbidities by overcoming technical hurdles through advanced computation. No clinical results have been published as of June 2025.

Therapeutic areas: Metabolic DisordersEndocrinologyCardiovascularNephrology
Modalities: BiologicProteinRecombinant protein
Industry: Biotech

Drug pipeline

1 asset

AP-23 Point of Care System

Pre-clinical

Partnerships

Undisclosed pharmaceutical companies

Beyond the preview

Go deeper on Fable Biyoteknoloji.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fable Biyoteknoloji.

Explore the full profile